EQL Pharma's management aiming for 30% Revenue Growth in 5 Years

Published
21 Feb 25
Updated
10 May 25
Mandelman's Fair Value
SEK 86.37
3.2% undervalued intrinsic discount
10 May
SEK 83.60
Loading
1Y
48.2%
7D
-13.4%

Author's Valuation

SEK 86.4

3.2% undervalued intrinsic discount

Mandelman's Fair Value

Shared on10 May 25
Fair value Decreased 29%

Mandelman made no meaningful changes to valuation assumptions.

Shared on13 Mar 25
Fair value Increased 53%

Mandelman has increased revenue growth from 19.0% to 30.0%, decreased profit margin from 17.0% to 15.0% and increased future PE multiple from 22.5x to 25.0x.

Shared on23 Feb 25
Fair value Increased 2.28%

Mandelman made no meaningful changes to valuation assumptions.

Shared on22 Feb 25
Fair value Increased 8.89%

Mandelman has decreased revenue growth from 22.0% to 19.0%, increased profit margin from 13.0% to 17.0% and increased discount rate from 4.8% to 6.0%.